These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25329226)

  • 1. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults.
    Zervou FN; Zacharioudakis IM; Mylonakis E
    Ann Intern Med; 2014 Oct; 161(8):JC9. PubMed ID: 25329226
    [No Abstract]   [Full Text] [Related]  

  • 2. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin or oritavancin for skin infections.
    Cormican M
    N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925
    [No Abstract]   [Full Text] [Related]  

  • 4. Dalbavancin or oritavancin for skin infections.
    Corey GR; Jiang H; Moeck G
    N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
    [No Abstract]   [Full Text] [Related]  

  • 5. Dalbavancin or oritavancin for skin infections.
    Baang J; Fisher S
    N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
    [No Abstract]   [Full Text] [Related]  

  • 6. Dalbavancin or oritavancin for skin infections.
    Núñez-Núñez M; Rodríguez-Baño J
    N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923
    [No Abstract]   [Full Text] [Related]  

  • 7. Dalbavancin or oritavancin for skin infections.
    Boucher HW; Talbot GH; Dunne MW
    N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacology and the treatment of complicated skin and skin-structure infections.
    Chambers HF
    N Engl J Med; 2014 Jun; 370(23):2238-9. PubMed ID: 24897088
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
    Gupta AK; Foley KA; Abramovits W; Rosen T
    Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
    [No Abstract]   [Full Text] [Related]  

  • 11. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin.
    Anderson VR; Keating GM
    Drugs; 2008; 68(5):639-48; discussion 649-51. PubMed ID: 18370443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin approved for acute skin infections.
    Traynor K
    Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
    Dunne MW; Zhou M; Darpo B
    Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.